COVID-19 Pharmacy Practice Considerations Series - Multisystem Inflammatory Syndrome in Children in COVID-19: Diagnosis, Management, and Relationship to Kawasaki Disease

June 11, 2020

The educational series will provide resources and updated guidance for pharmacists and pharmacy technicians on the pharmacy practice considerations needed for the management of COVID-19 patients, including shortage mitigation, pharmacotherapy options, emergency preparedness, and medication safety.

Target Audience

Pharmacist

Pharmacy Tech

Learning Objectives

Pharmacist
1.    Describe Multisystem Inflammatory Syndrome in Children (MIS-C) and the timing of its onset in relation to SARS-CoV-2 infection.
2.    Explain the mechanisms by which viruses can induce autoimmune reactions and the role of immunomodulating agents in the management of MIS-C.  
3.    Outline Kawasaki disease diagnosis and treatment, relating to MIS-C.
4.    Identify ongoing research for pediatric inflammatory syndromes.
Pharmacy Tech
1.    Identify immunomodulators that have a potential role in the management of MIS-C.
2.    Recall dosing, labeling, and administration information for IVIG.
 

Additional Information

AttachmentSize
Information for CE124.92 KB
Helpful Tips for Users23.36 KB
Presentation6.25 MB
Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CEU – Attendance
Course opens: 
06/03/2020
Course expires: 
07/26/2020
Event starts: 
06/11/2020 - 1:00pm
Event ends: 
06/11/2020 - 2:00pm
Cost:
$0.00
Live via webinar
United States

Relevant financial relationships: None of the planning committee have anything to disclose.  


Michael Portman will discuss off-label use of drugs and investigative use of drugs. Please describe: Use of TNF antagonists such as Etanercept and Infliximab for Kawasaki Disease.

Michelle Rychalsky will discuss off-label use of drugs. Please describe: I will discuss the role of interleukin-1 and interleukin-6 inhibitors (e.g. anakinra, tocilizumab), as well as corticosteroids, for management of Multisystem Inflammatory Syndrome in Children (MIS-C). I will discuss investigative use of drugs. Please describe: I will mention that remdesivir is an antiviral currently available via compassionate and emergency use, and that is currently being studied, for management of SARS-CoV-2 infection in children.   

 

Planning committee members
Jackie Stokes, BS
Manager, Pharmacy Program Services
Vizient

Gretchen Brummel
PharmD, BCPS
Pharmacy Executive Director
Vizient

Katrina Harper
PharmD, MBA, BCPS, BCSCP
Clinical Pharmacy Director
Vizient

Course reviewer
Katrina Harper
PharmD, MBA, BCPS, BCSCP
Clinical Pharmacy Director
Vizient

Presenters
Michael A. Portman, MD
Director, Pediatric Cardiovascular Research
Professor of Pediatrics
Seattle Children’s Hospital

Michelle Rychalsky, PharmD, BCPS
Senior Clinical Pharmacy Specialist
Yale New Haven Children's Hospital

Joint Accreditation Statement:

In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation Statements:

PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours. 
JA0006103-0000-20-103-L04-P - JA0006103-0000-20-103-L04-T


CEU
Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).
 

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CEU – Attendance

Price

Cost:
$0.00
Please login or register to take this course.